Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 8, 2011, Pages 1056-1062

  Froldi, Guglielmina ^a   Bertin, Riccardo ^a   Dorigo, Paola ^a   Montopoli, Monica ^a   Caparrotta, Laura ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

adrenergic receptors; Clopidogrel; P2 receptors; Ticlopidine; Vasorelaxation

Indexed keywords

ACETYLCHOLINE; BETA 2 ADRENERGIC RECEPTOR; CLOPIDOGREL; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; AORTA MEDIA; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; MALE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER;

ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; ANIMALS; ARTERIES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MALE; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; TICLOPIDINE; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 79959900549     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01313.x     Document Type: Article

References (38)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
2. Foster CJ et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598. (Pubitemid 32574645)
3. Hollopeter G et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207. (Pubitemid 32144286)
4. Uchiyama S et al. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006; 21(Suppl. 1): 7-16. (Pubitemid 43254156)
5. Mills DC et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-436.
6. 3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-777.
7. Gachet C et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-444.
8. Savi P et al. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-255. (Pubitemid 28312689)
9. Savi P et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-317. (Pubitemid 24251300)
10. Pereillo JM et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295.
11. Ding Z et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003; 101: 3908-3914. (Pubitemid 36857866)
12. Farid NA et al. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-142.
13. Savi P et al. Importance of hepatic metabolism in the anti-aggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-532.
14. Molero L et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 2005; 146: 419-424. (Pubitemid 41486684)
15. Heitzer T et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648-1652. (Pubitemid 44288996)
16. Jawien J et al. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol 2007; 556: 129-135. (Pubitemid 46074012)
17. Yang LH, Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997; 86: 479-491. (Pubitemid 27314907)
18. Yang LH et al. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998; 92: 83-89. (Pubitemid 28481387)
19. Weber AA et al. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999; 126: 415-420.
20. Jakubowski A et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 139-145. (Pubitemid 40051231)
21. Campbell JH et al. Cytodifferentiation and expression of alpha-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Correlation with cell density and proliferative state. Arteriosclerosis 1989; 9: 633-643. (Pubitemid 19236897)
22. Chiba K et al. Simultaneous evaluation of cell viability by neutral red, MTT and crystal violet staining assays of the same cells. Toxicology In Vitro 1998; 12: 251-258.
23. Arnal J-F et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55: 1078-1087. (Pubitemid 29361074)
24. Shanks RG. Clinical pharmacology of vasodilatory beta-blocking drugs. Am Heart J 1991; 121: 1006-1011.
25. Stork AP, Cocks TM. Pharmacological reactivity of human epicardial coronary arteries: phasic and tonic responses to vasoconstrictor agents differentiated by nifedipine. Br J Pharmacol 1994; 113: 1093-1098. (Pubitemid 24364382)
26. Dunn PM, Blakeley AG. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol 1988; 93: 243-245. (Pubitemid 18042809)
27. von Kugelgen I et al. Effects of suramin and alpha, betamethylene ATP indicate noradrenaline-ATP co-transmission in the response of the mouse vas deferens to single and low frequency pulses. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 760-763.
28. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005; 108: 180-192. (Pubitemid 41528788)
29. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006; 110: 415-432.
30. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59. (Pubitemid 36735258)
31. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009; 360: 411-413.
32. Wihlborg AK et al. ADPreceptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-1815.
33. Högberg C et al. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 2010; 142: 187-192.
34. Godfraind T. Classification of calcium antagonists. Am J Cardiol 1987; 59: 11B-23B.
35. Herbert JM, Savi P. Non-specific inhibition of ADP-induced platelet antiaggregation by clopidogrel in vitro. Thromb Haemost 1999; 82: 156-157. (Pubitemid 29368795)
36. Inoue M et al. The anti-platelet agent, ticlopidine, upregulates interleukin-1-beta-stimulated nitric oxide production in cultured rat vascular smooth muscle cells. Exp Nephrol 2002; 10: 267-274. (Pubitemid 34827784)
37. Ziemianin B et al. Thienopyridines: effects on cultured endothelial cells. J Physiol Pharmacol 1999; 50: 597-604. (Pubitemid 30022138)
38. Hu CJ et al. Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-alpha stimulated human umbilical vein endothelial cells. J Biomed Biotechnol 2009; doi:10.1155/2009/917837.